Novo Nordisk A/S Sponsored ADR (NVO)
Ozempic maker stock just collapsed
Shares of Danish pharmaceutical giant Novo Nordisk (NYSE: NVO), behind the weight-loss drug Wegovy and diabetes medication Ozempic, tumbled on Tuesday after the company slashed its full-year 2025 guidance, triggering a sharp sell-off from investors.
Novo Nordisk issues profit warning as competition — legal and otherwise — hits Wegovy, Ozempic
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic and Wegovy.
Novo Nordisk Stock Plummets After Ozempic Maker's Shock Cut to U.S. Outlook
The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and Ozempic in the U.S. market.
Novo Nordisk Cuts Guidance as Copycat Versions of Wegovy Hurt Results
The pharmaceutical giant said multiple entities were still marketing and selling unbranded versions of its drug despite U.S. regulators ordering an end to the practice.
Shares of Novo Nordisk plunge 15% after Wegovy-maker cuts full-year guidance
Danish pharmaceutical giant Novo Nordisk on Tuesday cuts its full-year sales and profit guidance.
3 'Wide Moat' SWANs
Despite a greedy market, we've found three quality stocks - NVO, RGA, and CP - offering strong value, growth, and reliable dividends. Novo Nordisk leads obesity treatment with strong GLP-1 drugs, a robust pipeline, and a 3.1% yield, trading well below historical P/E. Reinsurance Group of America is an undervalued, financially sound dividend grower with global reach and double-digit earnings growth potential.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk (NVO) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novo Nordisk: Undervalued Despite Strong Growth Trend & Solid Market Share
I am bullish on Novo Nordisk due to its 62% global GLP-1 market share and dominant Ozempic sales, supporting long-term leadership. Novo Nordisk's diversified GLP-1 portfolio, including Rybelsus and pending pill versions, positions it well against competitors and broadens its addressable market. Consistent double-digit revenue and profit growth, plus strong Q2 2025 expectations, reflect robust demand and effective cost management.
Here's Why Novo Nordisk (NVO) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novo Nordisk: The Market Hasn't Given It Enough Respect
Healthcare stocks have lagged the S&P 500, with Novo Nordisk already hit hard by intense competition from Eli Lilly. Despite recent setbacks and a decelerating growth outlook, Novo Nordisk's valuation now reflects steep pessimism, suggesting the downside appears limited. Novo Nordisk's robust brand, R&D, and profit margins provide a significant moat, even as competition in the GLP-1 market intensifies.
Novo Nordisk's Moat Is Deeper Than You Think
Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally. Obesity drug sales surged 65% YoY in Q1-FY25, driving total revenue growth of 18% and free cash flow of $1.38 billion. The company projects FY25 free cash flow between $8.14–$9.59 billion, supported by 48.43% EBIT margins and expanding manufacturing capacity.
